Novan Therapeutics' Abstract Accepted for Poster Session at 2014 Society for Investigative Dermatology Annual Meeting
Company to Present Poster on Phase 2 Study Results of Lead Product Candidate SB204 for the Treatment of Acne Vulgaris on May 8, 2014
DURHAM, NC (April 23, 2014) – Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, announced that data from the Phase 2 clinical trial in acne vulgaris with its lead product candidate, SB204, has been accepted for presentation at the 2014 Annual Meeting of the Society for Investigative Dermatology (SID) May 7-10, 2014 at the Albuquerque Convention Center in Albuquerque, New Mexico.
Abstract ID Number LB838: "Phase 2 study of efficacy and safety of SB204 in the treatment of acne vulgaris," J. Rico, J. Quiring, S. Hollenbach, C. Enloe, N. Stasko
Presenter: M. Joyce Rico, M.D., Chief Medical Officer, Novan Therapeutics
Poster Session: Session I
Session Date and Time: Thursday, May 8, 2014; 10:00 a.m. – 12:00 p.m. MT
“The statistically significant results Novan recently reported from the Company’s Phase 2 study of SB204 are very encouraging, and I look forward to presenting our efficacy and safety data at this prestigious dermatology conference,” said Dr. Rico. “The very recent news on attempts at further consolidation in the dermatology industry underscores the need for new drugs. At Novan we’re mindful of the shortcomings of currently available therapies and are focused on bringing more effective treatments to market that improve the quality of life for patients.”
SB204 is Novan's lead drug candidate for the treatment of acne vulgaris. During the phase 2 study, subjects treated with SB204 had improvement in inflammatory and non-inflammatory lesion counts at week 4, and the end of treatment (12 weeks). At four weeks, the 4% dose of SB204 demonstrated a statistically significant reduction in both noninflammatory (white heads and black heads) and inflammatory lesions (larger red bumps and pustules) compared to Vehicle (p ≤ 0.05, intent-to-treat analysis). Statistically significant reductions were also observed in both lesion counts at the 12 week time point.
About Novan, Inc.
Novan Therapeutics is a privately-held, clinical-stage specialty pharmaceutical company bringing the power of nitric oxide therapeutics to dermatology and wound care. Novan's core technologies solve the previous delivery issues with nitric oxide by storing the gaseous species on macromolecules that result in a diverse pipeline of "timed-release" nitric oxide-releasing new chemical entities. Novan is currently developing a range of drug products including topical gels, creams, ointments, and wound dressings which can be tailored to treat specific skin conditions.
To learn more about Novan Therapeutics, please visit www.novantherapeutics.com.
Julia Brannan, Pascale Communications, LLC, on behalf of Novan Therapeutics